Syncona Limited
Result of Annual General
Meeting
6 August 2024
At the Annual General Meeting of Syncona
Limited (the "Company")
held today, all Resolutions as set out in the 'Notice of the 2024
Annual General Meeting' dated 3 July 2024 sent to shareholders of
the Company (the "Notice")
were duly passed.
Resolutions 1 to 12 were proposed as Ordinary
Resolutions. Resolution 13 was proposed as a Special Resolution and
Resolution 14 was proposed as an Extraordinary
Resolution.
Details of the proxy voting results, which
should be read alongside the Notice, are noted below:
|
No
|
Resolution
|
For
|
Discretion
|
Against
|
Abstain (withheld)
|
|
1
|
Receive and consider the Annual Audited
Financial Statements of the Company for the year ended 31 March
2024, together with the Reports of the Directors and Auditors
therein
|
487,893,906
(99.99%)
|
(0)
(0%)
|
8,329
(0.01%)
|
516,479
|
|
2
|
Re-appointment of Deloitte LLP (Guernsey
Branch) as Auditors
|
477,577,926
(99.98%)
|
(0)
(0%)
|
71,702
(0.02%)
|
10,769,086
|
|
3
|
Authorise the Directors to determine the
remuneration of the Auditors
|
477,634,135
(99.99%)
|
(0)
(0%)
|
21,314
(0.01%)
|
10,763,265
|
|
4
|
Re-elect Melanie Gee as a Director
|
485,153,484
(99.44%)
|
(0)
(0%)
|
2,748,702
(0.56%)
|
516,528
|
|
5
|
Re-elect Julie Cherrington as a
Director
|
487,856,391
(99.99%)
|
(0)
(0%)
|
45,795
(0.01%)
|
516,528
|
|
6
|
Re-elect Cristina Csimma as a
Director
|
487,826,744
(99.98%)
|
(0)
(0%)
|
75,442
(0.02%)
|
516,528
|
|
7
|
Re-elect Virginia Holmes as a
Director
|
485,146,832
(99.44%)
|
(0)
(0%)
|
2,755,354
(0.56%)
|
516,528
|
|
8
|
Re-elect Robert Hutchinson as a
Director
|
485,091,732
(99.42%)
|
(0)
(0%)
|
2,808,954
(0.58%)
|
518,028
|
|
9
|
Re-elect Kemal Malik as a Director
|
485,094,236
(99.42%)
|
(0)
(0%)
|
2,806,450
(0.58%)
|
518,028
|
|
10
|
Re-elect Gian Piero Reverberi as a
Director
|
485,095,482
(99.42%)
|
(0)
(0%)
|
2,806,704
(0.58%)
|
516,528
|
|
11
|
Approve the report on implementation of the
Remuneration Policy for Non-Executive Directors
|
487,781,294
(99.97%)
|
(0)
(0%)
|
123,008
(0.03%)
|
514,412
|
|
12
|
Authority to allot and issue shares, as set out
in the Notice
|
475,216,648
(99.84%)
|
(0)
(0%)
|
784,717
(0.16%)
|
12,417,349
|
|
13
|
Authorise the Company to purchase its own
shares, as set out in the Notice
|
487,879,475
(99.99%)
|
(0)
(0%)
|
27,221
(0.01%)
|
512,018
|
|
14
|
Disapply pre-emption rights, as set out in the
Notice
|
469,084,312
(98.55%)
|
(0)
(0%)
|
6,914,778
(1.45%)
|
12,419,624
|
|
|
|
|
|
|
| |
A
vote withheld is not a vote in law and has not been counted in the
votes for and against a resolution.
In accordance with the UK Listing
Rule 6.4.2R, a copy of all the resolutions passed other than
resolutions concerning ordinary business have been submitted to the
Financial Conduct Authority via the National Storage Mechanism and
will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions can
be found in the Notice, a copy of which is available on the
Company's website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/.
Enquiries
Syncona Limited
Natalie Garland-Collins / Fergus Witt
Tel: +44 (0) 20 3981
7940
FTI Consulting
Ben Atwell / Tim Stamper
Tel: +44 (0) 20 3727 1000
About
Syncona:
Syncona's
purpose is to invest to extend
and enhance human life. We do this by creating, building and
scaling companies to deliver transformational treatments to
patients in areas of high unmet need.
We aim to build and maintain a
diversified portfolio of 20-25 globally leading life science
businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on
developing treatments that deliver patient impact by working in
close partnership with world-class academic founders and
experienced management teams. Our balance sheet underpins our
strategy, enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options,
build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.
Syncona Limited seeks to achieve
returns over the long term. Investors should seek to ensure they
understand the risks and opportunities of an investment in Syncona
Limited, including the information in our published documentation,
before investing.